瓣膜切除术与瓣膜置换术治疗三尖瓣感染性心内膜炎的外科疗效比较
单中心回顾性研究纳入2012至2016年63例因感染性三尖瓣心内膜炎行手术的成人患者,比较瓣膜切除术、修复术与置换术。三组30天手术死亡率相似,瓣膜切除组随访1年非计划再入院率显著更低。作者认为瓣膜切除术可作为高危患者初始治疗策略的一部分,但需进一步研究长期结局。
要点
- 三组30天手术死亡率相似,出血再手术、卒中、延长通气、ICU停留及总住院时间无显著差异。
- 瓣膜切除组随访1年非计划再入院率显著低于修复组和置换组。
- 瓣膜修复组年龄更大(46岁 vs 切除组29岁、置换组31岁),高血压和肌酐升高更多。
核心结论
- 三尖瓣感染性心内膜炎患者行瓣膜切除、修复或置换的30天手术死亡率相似。
- 瓣膜切除组随访1年非计划再入院率显著更低。
- 瓣膜切除术可作为该高危人群的初始治疗,作为识别最终适合瓣膜置换患者的外科策略的一部分。
- 需要进一步研究长期结局和生存。
研究设计与样本
- 单中心心脏外科数据库回顾性查询,纳入2012至2016年年龄大于18岁因感染性心内膜炎行三尖瓣手术的患者。
- 共63例患者,按手术类型分为瓣膜切除组、修复组和置换组。
- 比较术前因素与结局,包括死亡、住院时间和并发症。
主要发现
- 瓣膜修复组年龄大于切除组和置换组(46岁 vs 29岁和31岁;p=0.007)。
- 瓣膜修复组高血压、肌酐升高更多,弥漫性双侧肺栓塞发生率更低。
- 金黄色葡萄球菌属是最常见病原体。
- 死亡、出血需再手术、重大卒中、延长通气时间、ICU停留和总住院时间在各组间相似。
- 初始瓣膜切除患者中36%在1年时可随访,凸显静脉药物滥用队列的随访挑战。
临床怎么用
- 作者认为瓣膜切除术可作为该高危人群的初始治疗,作为识别最终适合瓣膜置换患者的外科策略的一部分。
- 作者指出需要进一步研究长期结局和生存。
局限性
- 初始瓣膜切除患者中仅36%在1年时可随访,凸显静脉药物滥用队列的随访挑战。
- 需要进一步研究长期结局和生存。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Optimal surgical treatment of infective tricuspid endocarditis is debatable, especially in the setting of inherent social and pathologic concerns. This study compared tricuspid valve repair, replacement, and excision for the treatment of infective endocarditis METHODS: A single-center cardiac surgery database was queried to identify patients aged older than 18 years who underwent tricuspid valve operations for infective endocarditis between 2012 and 2016. Patients were divided into three groups by the type of tricuspid valve operation: valvectomy, repair, or replacement. Patients were evaluated to identify differences between preoperative factors and outcomes, including death, length of stay, and complications. RESULTS: During the study period, 63 patients underwent surgical treatment of infective tricuspid valve endocarditis. Demographic and baseline characteristics were comparable across all groups, except that the valve repair group was older compared with valvectomy and replacement (46 vs 29 and 31 years, respectively; p = 0.007), with more hypertension, elevated creatinine, and a lower incidence of diffuse, bilateral pulmonary emboli. Staphylococcus species were the most common organisms. The incidence of death, bleeding requiring reoperation, major stroke, prolonged ventilator time, intensive care unit stay, and overall hospital length of stay were similar in all groups. Of patients undergoing initial valvectomy, 36% were available for follow-up at 1 year, highlighting the challenges associated with the intravenous drug abuse cohort. Patients who underwent tricuspid valvectomy in the group available for follow-up had significantly lower unplanned readmission rates at 1 year. CONCLUSIONS: Tricuspid valve endocarditis patients who undergo tricuspid valve excision, repair, and replacement have similar 30-day operative mortality, as defined by The Society of Thoracic Surgeons. Excision patients have significantly lower unplanned readmission rates at 1 year. Tricuspid valvectomy is an acceptable initial treatment in this high-risk group as part of a surgical strategy to identify patients who are candidates for eventual valve replacement. Further study of long-term outcomes and survival is warranted.
引用
- Protos AN, Trivedi JR, Whited WM, et al. Valvectomy Versus Replacement for the Surgical Treatment of Tricuspid Endocarditis. Ann Thorac Surg. 2018. PMID: 29777672. doi:10.1016/j.athoracsur.2018.04.051
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。